Useful Advices - Business

If you have done any research on AIM in the past you already know that it is growing quite rapidly. Last year it grew by 500 new comp

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

anies; an increase compared to the 355 new companies that joined in 2003. Along with the growing number of companies flocking to AIM

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

re eager investors, who are willing to take advantage of investment opportunities in smaller and newer companies rather than put thei

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

money into the big ones.

In particular, companies are eager to list on AIM for several reasons. In the first place, new companies s

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

ee it as an opportunity to grow without all the restrictions and hindrances put in place by the main markets and many international e

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

changes. For example, if a company cannot provide the required trading record to float on the main market, the only alternative might

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

be AIM. The Sarbanes-Oxley corporate governance rules in the U.S. are also a concern for many American companies that want to go publ

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

ic.

Softer regulations and lower costs make AIM an attractive market, especially for smaller companies that have no other way of rai

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

ing the funds necessary to sustain continued growth. AIM makes it easier for these companies to take that next step. Overseas firms f

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

nd AIM easier to break into than other markets as well.

Of course, if you list on AIM, many investors will be attracted to investing

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

in your company because of the potential to rein in huge profits if your stock grows at a rapid rate. Private investors can get in at

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

the beginning and benefit from the growth that may follow. Larger companies don’t have the tendency to grow in leaps and bounds as t

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

eir younger counterparts do.

But is this market too risky for some investors, and as such, not quite as enticing for companies as it

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

might seem at first glance? This really depends on what your company’s needs are and what you’re looking to gain from the market. Alt

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

hough the UK is actively seeking to attract more companies from the U.S., there are worries among American companies that AIM might n

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

t be worth the risk.

In addition, more and more foreign companies (that follow different reporting and corporate governance standard

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

) and lower-quality UK-based firms are joining AIM, and some analysts worry that overall, the shares are overpriced. And rumors are f

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

lying that IHT relief on AIM shares might be scrapped in the near future, which would cause investors to start a massive sell-off.

O

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

course, only time will tell whether or not the potential problems surrounding AIM are temporary or deep-seated. There are both risks

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

and benefits to listing on AIM, so in the end, the decision your company makes rests on factors specific to your particular situation

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.usefuladvices.org.ua/article/3843/usefuladvices-Does-AIM-Live-Up-to-the-Hype.html">Does AIM Live Up to the Hype?</a>

BB link (for phorums):
[url=http://www.usefuladvices.org.ua/article/3843/usefuladvices-Does-AIM-Live-Up-to-the-Hype.html]Does AIM Live Up to the Hype?[/url]

There are plenty of things you can do to help reduce event-day challenges in the planning marketplace- making use of event planning software, choosing your venue and suppliers based on careful research, automating as much as possible, etc.

For most of us, the start of a new year is a time of reflection. A review of the year gone by and an opportunity to set goals for the year ahead. Intentions are good and motivation is high. The challenge lies in the predictable loss of steam that ensues as we move past the holiday season and back into our workaday lives. Here are some strategies to assist you in seeing those New Year's goals and resolutions come to life.

Want to get your calls returned? Quickly? These seven tips will add top-notch courtesy to your voicemail practices and increase your likelihood of getting your calls (happily) returned.

Tags

Links

Useful Advices - Does AIM Live Up to the Hype?

Related Articles: